{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-165273","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.504182+00:00","generated_at":"2026-06-14T03:24:48.485533+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ionis closes $575M convertible notes offering, repurchases $434.1M of 2024 notes","bullets":["Issued $575M aggregate principal of 1.75% convertible senior notes due 2028, including full exercise of greenshoe.","Net proceeds approximately $560.8M after deducting discounts, commissions, and offering expenses.","Used $420.4M of net proceeds to repurchase $434.1M in aggregate principal of its 0.125% convertible notes due 2024.","Initial conversion price $53.73 per share, representing a 32.5% premium over the June 7, 2023 closing price of $40.55.","Remaining proceeds expected to fund additional 2024 note repurchases, repayment at maturity, and general corporate purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-165273","json":"https://secwatch.observer/filing/0001193125-23-165273.json","markdown":"https://secwatch.observer/filing/0001193125-23-165273.md","text":"https://secwatch.observer/filing/0001193125-23-165273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000119312523165273/0001193125-23-165273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000119312523165273/d511748d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:24:48.485533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d7bd30948cc162c004a7b04b61f2d8681ecc404","claim":"IONIS PHARMACEUTICALS INC incurred convertible notes of $575.0 million aggregate principal amount at 1.75% per year maturing June 15, 2028.","evidence_excerpt":"On June 12, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000119312523165273/0001193125-23-165273-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$575.0 million aggregate principal amount"},{"label":"Rate","value":"1.75% per year"},{"label":"Maturity","value":"June 15, 2028"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2557dc9d606f677ee9a462339ff437877529fd45","claim":"IONIS PHARMACEUTICALS INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $575.0 million aggregate principal amount (effective 2023-06-12).","evidence_excerpt":"On June 12, 2023, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $75.0 million principal amount of Notes.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874015/000119312523165273/0001193125-23-165273-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$575.0 million aggregate principal amount"},{"label":"Effective","value":"2023-06-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}